Search

Your search keyword '"[Acosta García,H"' showing total 12 results
Start Over Author "[Acosta García,H"
12 results on '"[Acosta García,H"'

5. PET usefulness in non-oncological indications

Author

Acosta García, Héctor, Isabel Gómez, Rebeca, Benot López, Soledad, [Acosta García,H, Isabel Gómez,R, and Benot López,S] AETSA Evaluación de Tecnologías Sanitarias de Andalucía.

Subjects
Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Tomography, Emission-Computed::Positron-Emission Tomography [Medical Subject Headings], Tomografía por emisión de positrones, Publication Type::Publication Formats::Bibliography::Biobibliography [Medical Subject Headings], Bibliografía, Evaluación de la Tecnología Biomédica, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Technology Assessment, Biomedical [Medical Subject Headings]
Abstract

Se estructura la información relativa a la utilidad o rendimiento diagnóstico de los diferentes radiofármacos que se utilizan en la PET, en las indicaciones no oncológicas establecidas en su ficha técnica. En base a la información localizada, puede ser conveniente la realización de un informe de evaluación de PET 18F-FDG en la indicación insuficiencia ventricular izquierda grave y la actualización de las revisiones sistemáticas de PET 18F-FDG en las indicaciones sarcoidosis y epilepsia temporal parcial refractaria a tratamiento médico. En el resto de las 15 indicaciones no procedería ni la realización de un informe ni la actualización de las información disponible. Yes

Published
2019

6. Velmanasa alfa en el tratamiento de la alfa-manosidosis: eficacia y seguridad

Author

Acosta García, Héctor and [Acosta García,H] AETSA Evaluación de Tecnologías Sanitarias de Andalucía.

Subjects
Evidence-based medicine, Disciplines and Occupations::Health Occupations::Medicine::Clinical Medicine::Evidence-Based Medicine [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Enzyme Therapy::Enzyme Replacement Therapy [Medical Subject Headings], Oligosaccharides, Diseases::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Metabolism, Inborn Errors::Carbohydrate Metabolism, Inborn Errors::Mannosidase Deficiency Diseases::alpha-Mannosidosis [Medical Subject Headings], Alpha-Mannosidosis, Chemicals and Drugs::Carbohydrates::Polysaccharides::Oligosaccharides [Medical Subject Headings], Medicina basada en la evidencia, Alfa-manosidosis, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy [Medical Subject Headings], Diseases::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Metabolism, Inborn Errors::Lysosomal Storage Diseases::Mannosidase Deficiency Diseases::alpha-Mannosidosis [Medical Subject Headings], Quimioterapia, Drug therapy, Síntesis de la evidencia I, Resultado del tratamiento, Treatment outcome, Terapia de reemplazo enzimático, Oligosacáridos, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]
Abstract

Se evalúa la eficacia y seguridad de velmanasa alfa en el tratamiento de la alfa-manosidosis a través de una revisión rápida que sirve de apoyo para el posicionamiento terapéutico. Velmanasa alfa ha demostrado tener actividad biológica a través de la reducción de oligosacáridos plasmáticos. En cuanto a variables con más relevancia clínica como variables funcionales asociadas a la enfermedad, no ha conseguido mostrar diferencias significativas frente a placebo, aunque se aprecia una tendencia más favorable en los pacientes tratados. El perfil de seguridad es aceptable con eventos adversos leves de hipersensibilidad y asociados a la perfusión. Yes

Published
2018

7. Zalmoxis como tratamiento adyuvante en el trasplante haploidéntico de progenitores hematopoyéticos: eficacia y seguridad

Author

Acosta García, Héctor, Alfaro Lara, Eva Rocío, [Acosta García,H, and Alfaro Lara,ER] AETSA Evaluación de Tecnologías Sanitarias de Andalucía.

Subjects
Transplantation, Graft vs host disease, Anatomy::Cells::Stem Cells::Hematopoietic Stem Cells [Medical Subject Headings], Enfermedad injerto contra huésped, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation [Medical Subject Headings], Tolerancia al trasplante, Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy [Medical Subject Headings], Trasplante haploidéntico, Celulas madre hematopoyeticas, Phenomena and Processes::Immune System Phenomena::Immune System Processes::Immunomodulation::Immune Tolerance::Transplantation Tolerance [Medical Subject Headings], Quimioterapia, Drug therapy, Resultado del tratamiento, Treatment outcome, Hematopoietic stem cells, Transplantation, haploidentical, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]
Abstract

Se evalúa la eficacia y seguridad de Zalmoxis® como tratamiento adyuvante en el trasplante haploidéntico de progenitores hematopoyéticos, a través de una revisión rápida que sirve de apoyo para el posicionamiento terapéutico. Zalmoxis®, a través de un mecanismo de acción novedoso, produce una mejora en la reconstitución inmune de los pacientes sometidos a trasplante, lo que podría traducirse en una mejora en la supervivencia. Sin embargo la evidencia que apoya esta afirmación es de baja calidad. El fármaco es bien tolerado, siendo la enfermedad de injerto contra huésped el principal evento adverso, que se controla con la administración de gancicliovir. Yes

Published
2018

8. Guía de Terapéutica Antimicrobiana del Área Aljarafe, 3ª edición

Author

Acosta García, Héctor, Aibar Remón, Carlos, Alcázar, Francisco Javier, Alonso, Maria Teresa, Alvarado Fernández, Dolores, Anaya Ordóñez, Sonia, Anguis, Juan Ignacio, Aspíroz Sancho, Carmen, Aznar Martín, Javier, Beltrán Calvo, Carmen, Benavente, Regina Sandra, Bernabeu Wittel, José, Bravo Escudero, Carmen, Campa, Azucena de la, Campo Gracia, Angel del, Campos, Juan Miguel, Cansino Romero, Francisco Javier, Carlos Gil, Ana M., Cantudo Cuenca, M. Dolores, Catalán, José Manuel, Chavez Caballero, Mónica, Corbi Llopis, Rosa, Corral Baena, Susana, Cots, Josep María, Cruces Jiménez, José Miguel, Cruz Navarro, Natalio, Cuétara, Marisol, Cueto, Marina de, Delgado de la Cuesta, Juan, Domínguez Cruz, Javier, Domínguez Jiménez, Mª Carmen, Espín, Beatriz, Espinosa Calleja, Ricardo, Expósito García, Sebastián, Fernández Moyano, Antonio, Fernández Urrusuno, Rocío, Flores Dorado, Macarena, Franco Alvarez de Luna, Francisco, Franco Márquez, M. Luisa, Galván Banqueri, Mercedes, Garabito Sánchez, M. José, García Estepa, Raúl, García Jiménez, Emilio, García López, José Luis, García Moreno, Mercedes, García Sánchez, Cristina, García de la Vega Sosa, Manuel, Garrido Arce, Macarena, Gilaberte Calzada, Yolanda, Huguet, Montse, Jiménez Pavón, Maria Luisa, Giménez Júlvez, Teresa, Gómez Gómez, Maria José, Gómez Vázquez, Ana, Guerrero Casas, Aurora, Hernández, Francisco Javier, Jiménez Vizcaino, Beatriz, Laureano Zarza, Miguel, Lepe Jiménez, José Antonio, Llor, Carles, López Cerero, Lorena, Manzano, M. Carmen, Marmesat, Francisco, Martín Grutmancher, Fernando, Martín Márquez, Fátima, Martínez Granero, Mercedes, Martínez-Gil Pardo de Vera, Cristina, Martínez Roda, M. José, Mata Martín, Ana, Merino de la Torre, Esther, Millán Cantero, Helena, Molina Linde, Juan Máximo, Montero Balosa, M. Carmen, Montes Sánchez, María del Carmen, Muñoz Yribarren, Cristina, Olivencia Pérez, Miguel, Palacios Baena, Zaira R., Olmedo Rivas, Cinta, Palma Morgado, Daniel, Pascual Hernández, Álvaro, Pascual de la Pisa, Beatriz, Pereira Delgado, Consuelo M., Pérez Pérez, Pastora, Pérez Santos, M. Jesús, Periáñez Párraga, Leonor, Pinilla Cordero, Sonia, Poyato, Manuel, Praena Segovia, Julia, Ramírez Arcos, Mercedes, Reinosa Santiago, Alfredo, Retamar Gentil, Pilar, Rigueira, Ana, Robustillo Cortés, M. de las Aguas, Rodríguez Baño, Jesús, Rodríguez Benjumeda, Luis Miguel, Rodríguez Pappalardo, Vicente, Roldán Valenzuela, Andrés, Romero García, Ana, Rosario Lozano, M. Piedad, Ruiz Pérez de Pipaón, Maite, Sabalete Moya, Trinidad, Sánchez Fernández, Norma, Sánchez Moreno, María, Santos Lozano, José Manuel, Serrano Martino, Carmen, Solís de Dios, Miguel, Suárez Barrenechea, Anabel, Taboada Prieto, Salomé, Toro López, M. Dolores, Trueba Lawand, Araceli, Valera Rubio, Marta, Vázquez Florido, Antonio, Yanes Martín, Jaime, [Acosta García,H, Carlos Gil,AM, Galván Banqueri,M, García Estepa,R,Molina Linde,JM, Robustillo Cortés,MA, Rosario Lozano,MP, Sabalete Moya,T, Valera Rubio,M] Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. [Aibar Remón,C] Departamento de Microbiología, Medicina Preventiva y Salud Pública. Universidad de Zaragoza. Servicio de Medicina Preventiva y Salud Pública. Hospital Clínico Universitario Lozano Blesa. Zaragoza. [Alcázar,FJ,Campa,A, Campo Gracia,A, Cantudo Cuenca,MD, Catalán,JM, Chavez Caballero,M, Corral Baena,S, Delgado de la Cuesta,J, Espinosa Calleja,R, Expósito García,S, Fernández Moyano,A, Franco Márquez,ML, Garabito Sánchez,MJ, Garrido Arce,M, Gómez Vázquez,A, Hernández,FJ, Martín Márquez,F, Martínez Roda,MJ, Mata Martín,A,Merino de la Torre,E, Millán Cantero,H, Muñoz Yribarren,C, Olivencia Pérez,M, Olmedo Rivas,C, Pereira Delgado,CM, Poyato,M, Ramírez Arcos,M, Serrano Martino,C, Taboada Prieto,S, Trueba Lawand,A] Hospital San Juan de Dios del Aljarafe, Bormujos, Sevilla. [Alonso,MT, Aznar Martín,J, Bernabeu Wittel,J, Corbi Llopis,R, Cruz Navarro,N, Domínguez Cruz,J, Espín,B, García Sánchez,C, Gómez Gómez,MJ, Lepe Jiménez,JA, Praena Segovia,J, Ruiz Pérez de Pipaón,M, Vázquez Florido,A] Hospital Universitario Virgen del Rocío, Sevilla. [Alvarado Fernández,D, Cueto,M, López Cerero,L, Palacios Baena,ZR, Pascual Hernández,A, Retamar Gentil,P, Rodríguez Baño,J, Toro López,MD] Hospital Universitario Virgen Macarena, Sevilla. [Anaya Ordóñez,S] UGC Farmacia Granada Intercentros. [Anguis,JI, Beltrán Calvo,C, Bravo Escudero,C, Campos,JM, Cruces Jiménez,JM, Fernández Urrusuno,R, García de la Vega Sosa,M, Jiménez Pavón,ML, Guerrero Casas,A, Jiménez Vizcaino,B, Laureano Zarza,M, Marmesat,F, Martínez Granero,M, Montero Balosa,MC, Montes Sánchez,MC, Pascual de la Pisa,B, Pinilla Cordero,S, Reinosa Santiago,A, Rodríguez Benjumeda,LM, Rodríguez Pappalardo,V, Roldán Valenzuela,A, Romero García,A, Sánchez Fernández,N, Solís de Dios,M, Yanes Martín,J] Distrito Sanitario Aljarafe-Sevilla Norte, Servicio Andaluz de Salud, Sevilla. [Aspíroz Sancho,C] Hospital Royo Villanova, Zaragoza. [Benavente,RS, Domínguez Jiménez,MC] Área de Gestión Sanitaria de Osuna, Sevilla. [Cansino Romero,FJ] Residencia Geriátrica Montetabor. Bollullos de la Mitación, Sevilla. [Cuétara,M] Servicio de Microbiología del Hospital Severo Ochoa de Leganés, Madrid. [Flores Dorado,M] Área de Gestión Sanitaria Norte de Cádiz, Cádiz. [Franco Alvarez de Luna,F] Hospital de Ríotinto, Huelva. [García López,JL, Suárez Barrenechea,A] Servicio de Microbiología, Hospital Virgen de Valme, Sevilla. [García Moreno,M] Residencia de Mayores de la Junta de Andalucía Huerta Palacio. Dos Hermanas, Sevilla. [Gilaberte Calzada,Y, Giménez Júlvez,T] Hospital Miguel Servet, Zaragoza. [Huguet,M] Residencia CER Espartinas, Espartinas, Sevilla. [Martínez-Gil Pardo de Vera,C] Area de Gestión Sanitaria Norte de Jaén, Jaén. [Palma Morgado,D, and Santos Lozano,JM] Distrito Sevilla, Sevilla. [Pérez Pérez,P] Observatorio para la Seguridad del Paciente. Agencia de Calidad Sanitaria de Andalucía. Sevilla. [Pérez Santos,MJ] Servicio Microbiología. Hospital de Ronda. Málaga. [Periáñez Párraga,L] Hospital Son Espases, Palma Mallorca. [Regueira,A] Hospital San Agustín, Avilés, Asturias. [Sánchez Moreno,M] Area de Gestión Sanitaria Sur de Sevilla, Sevilla.

Subjects
Uso de la información científica en la toma de decisiones en salud, Administración del Tratamiento Farmacológico, Usos terapéuticos, Toma de decisiones clínicas, Terapéutica, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics [Medical Subject Headings], Guía de tratamiento antimicrobiano, Andalucía, Health Care::Health Services Administration::Organization and Administration::Decision Making, Organizational [Medical Subject Headings], Publication Type::Publication Formats::Guideline::Practice Guideline [Medical Subject Headings], Guía de práctica clínica, Health Care::Health Care Facilities, Manpower, and Services::Health Services::Pharmaceutical Services::Medication Therapy Management [Medical Subject Headings], Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents [Medical Subject Headings], Antiinfecciosos, Antimicrobianos, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses [Medical Subject Headings]
Abstract

Coordinadora: Rocío Fernández Urrusuno. Co-coordinadora: Carmen Serrano Martino. Estas guías son un recurso indispensable en los Programas de Optimización de Antibióticos (PROA). No sólo constituyen una herramienta de ayuda para la toma de decisiones en los principales síndromes infecciosos, proporcionando recomendaciones para el abordaje empírico de dichos procesos, sino que son el patrón/estándar de referencia que permitirá determinar la calidad o adecuación de los tratamientos realizados. Las guías pueden ser utilizadas, además, como herramienta de base para la formación y actualización en antibioterapia, ya que permiten mantener actualizados los conocimientos sobre las nuevas evidencias en el abordaje de las infecciones. Por último, deberían incorporar herramientas que faciliten el proceso de toma de decisiones compartidas con el paciente. El objetivo de esta guía es proporcionar recomendaciones para el abordaje de las enfermedades infecciosas más prevalentes en la comunidad, basadas en las últimas evidencias disponibles y los datos de resistencias de los principales patógenos que contribuyan a mejorar la calidad de la prescripción de antimicrobianos. Yes

Published
2018

9. Nusinersén en el tratamiento de la atrofia muscular espinal: eficacia y seguridad

Author

Alfaro Lara, Eva R., Acosta García, Héctor, [Alfaro Lara,ER, and Acosta García,H] AETSA Evaluación de Tecnologías Sanitarias de Andalucía.

Subjects
Evidence-based medicine, Muscular atrophy, spinal, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::Nucleic Acid Probes::Antisense Elements (Genetics)::Oligonucleotides, Antisense [Medical Subject Headings], Oligonucleótidos antisentido, Medicina basada en la evidencia, Atrofia muscular espinal, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy [Medical Subject Headings], Diseases::Nervous System Diseases::Central Nervous System Diseases::Spinal Cord Diseases::Muscular Atrophy, Spinal [Medical Subject Headings], Oligonucleotides, antisense, Drug therapy, Quimioterapia, Treatment outcome, Resultado del tratamiento, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]
Abstract

Se evalúa la eficacia y seguridad de nusinersén en el tratamiento de la atrofia muscular espinal a través de una revisión rápida que sirve de apoyo para el posicionamiento terapéutico. Nusinersén ha demostrado ser eficaz en reducir el riesgo de muerte o ventilación permanente en bebés con AME tipo 1 frente a placebo, así como mejora en la función motora. En niños con AME 2 o 3, también ha demostrado beneficio frente placebo en función motora, aunque no se dispone de resultados en supervivencia ni función respiratoria. El perfil de seguridad parece favorable, con eventos adversos derivados de la administración lumbar. Yes

Published
2017

10. Computerized clinical decision support systems for prescribing in primary care: main characteristics and implementation impact-protocol of an evidence and gap map.

Author

Acosta-García H, Ferrer-López I, Ruano-Ruiz J, Santos-Ramos B, and Molina-López T

Subjects
Humans, Prescriptions, Primary Health Care, Systematic Reviews as Topic, Decision Support Systems, Clinical
Abstract

Background: Computerized clinical decision support systems are used by clinicians at the point of care to improve quality of healthcare processes (prescribing error prevention, adherence to clinical guidelines, etc.) and clinical outcomes (preventive, therapeutic, and diagnostics). Attempts to summarize results of computerized clinical decision support systems to support prescription in primary care have been challenging, and most systematic reviews and meta-analyses failed due to an extremely high degree of heterogeneity present among the included primary studies. The aim of our study will be to synthesize the evidence, considering all methodological factors that could explain these differences, and build an evidence and gap map to identify important remaining research questions., Methods: A literature search will be conducted from January 2010 onwards in MEDLINE, Embase, the Cochrane Library, and Web of Science databases. Two reviewers will independently screen all citations, full text, and abstract data. The study methodological quality and risk of bias will be appraised using appropriate tools if applicable. A flow diagram with the screened studies will be presented, and all included studies will be displayed using interactive evidence and gap maps. Results will be reported in accordance with recommendations from the Campbell Collaboration on the development of evidence and gap maps., Discussion: Evidence behind computerized clinical decision support systems to support prescription use in primary care has so far been difficult to be synthesized. Evidence and gap maps represent an innovative approach that has emerged and is increasingly being used to address a broader research question, where multiple types of intervention and outcomes reported may be evaluated. Broad inclusion criteria have been chosen with regard to study designs, in order to collect all available information. Regarding the limitations, we will only include English and Spanish language studies from the last 10 years, we will not perform a grey literature search, and we will not carry out a meta-analysis due to the predictable heterogeneity of available studies., Systematic Review Registration: This study is registered in Open Science Framework https://bit.ly/2RqKrWp., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

11. Intervention effectiveness by pharmacists integrated within an interdisciplinary health team on chronic complex patients.

Author

Acosta-García H, Alfaro-Lara ER, Sánchez-Fidalgo S, Sevilla-Sánchez D, Delgado-Silveira E, Juanes-Borrego A, and Santos-Ramos B

Subjects
Hospitalization, Humans, Length of Stay, Patient Care Team, Pharmacists, Quality of Life
Abstract

Background: Nowadays, it is difficult to establish a specific method of intervention by the pharmacist and its clinical repercussions. Our aim was to identify interventions by pharmacists integrated within an interdisciplinary team for chronic complex patients (CCPs) and determine which of them produce the best results., Methods: A systematic review (SR) was performed based on PICO(d) question (2008-18): (Population): CCPs; (Intervention): carried out by health system pharmacists in collaboration with an interdisciplinary team; (Comparator): any; (Outcome): clinical and health resources usage outcomes; (Design): meta-analysis, SR and randomized clinical trials., Results: Nine articles were included: one SR and eight randomized clinical trials. The interventions consisted mainly in putting in order the pharmacotherapy and the review of the medication adequacy, medication reconciliation in transition of care and educational intervention for health professionals. Only one showed significant improvements in mortality (27.9% vs. 38.5%; HR = 1.49; P = 0.026), two in health-related quality of life [according to EQ-5D (European Quality of Life-5 Dimensions) and EQ-VAS (European Quality of Life-Visual Analog Scale) tests] and four in other health-related results (subjective self-assessment scales, falls or episodes of delirium and negative health outcomes associated with medication). Significant differences between groups were found in hospital stay and frequency of visits to the emergency department. No better results were observed in hospitalization rate. Otherwise, one study measured cost utility and found a cost of €45 987 per quality-adjusted life year gained due to the intervention., Conclusions: It was not possible to determine with certainty which interventions produce the best results in CCPs. The clinical heterogeneity of the studies and the short follow-up of most studies probably contributed to this uncertainty., (© The Author(s) 2019. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.)

Published
2020
Full Text
View/download PDF

12. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.

Author

Cotrina-Luque J, Gil-Navarro MV, Acosta-García H, Alfaro-Lara ER, Luque-Márquez R, Beltrán-García M, and Bautista-Paloma FJ

Subjects
Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents adverse effects, Bacterial Load, Cross Infection diagnosis, Cross Infection microbiology, Double-Blind Method, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Penicillanic Acid administration & dosage, Penicillanic Acid adverse effects, Piperacillin administration & dosage, Piperacillin adverse effects, Piperacillin, Tazobactam Drug Combination, Pseudomonas Infections diagnosis, Pseudomonas Infections microbiology, Pseudomonas aeruginosa growth & development, Pseudomonas aeruginosa isolation & purification, Remission Induction, Spain, Time Factors, Treatment Outcome, Young Adult, Anti-Bacterial Agents administration & dosage, Cross Infection drug therapy, Penicillanic Acid analogs & derivatives, Pseudomonas Infections drug therapy, Pseudomonas aeruginosa drug effects
Abstract

Background: There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion., Objective: The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to Pseudomonas aeruginosa. Setting Multicenter clinical trial with 11 third level Spanish hospitals., Method: Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II)., Main Outcome Measure: Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported. Results 78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported., Conclusion: Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results